Henry Meds vs Ivim Health: Which GLP-1 Telehealth Wins? (2026)

If you want the simplest, most predictable cash-pay path to a compounded GLP-1, Henry Meds is the cleaner choice. Its flat-rate membership model is built to remove friction: a streamlined intake, a clinician review, and a known monthly cost, with compounded semaglutide or tirzepatide shipped to you. There is little to decode and few surprises on the invoice.

If you want clinical structure — provider visits, lab oversight, coaching, and a credible route toward a brand-name medication — Ivim Health is the stronger fit. Ivim positions itself less as a vending machine for compounded drugs and more as a managed program, which appeals to patients who want a clinician and a coach in their corner and who may prefer (or medically need) FDA-approved branded therapy rather than a compounded preparation.

Neither is universally "better." They optimize for different patients. The rest of this piece breaks down the dimensions that should drive your decision, and closes with picks by patient type.

It helps to be precise about what you are buying. Henry Meds and Ivim Health are telehealth platforms: they connect you, online, to clinicians licensed in your state. After an intake questionnaire and — depending on the platform — a synchronous or asynchronous review, a licensed provider decides whether a GLP-1 prescription is appropriate for you. If it is, the prescription is filled (for compounded products, by a compounding pharmacy the platform works with) and shipped.

What they are not: pharmacies you can buy medication from without a prescription. Neither platform lets you skip the clinical step. You cannot "order" a GLP-1 the way you order a supplement. A consultation with a licensed provider is required, and that provider can decline to prescribe. Any service that implies otherwise — or that offers "research chemicals" or grey-market vials without a prescription — should be avoided entirely; that is not what either of these companies does, and it is not something we would ever point a reader toward.

The GLP-1 medications themselves — semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound) — have been studied in large clinical trials and carry FDA-approved labeling for the brand-name products. According to those FDA labels and the manufacturers' published pivotal trials, average weight reduction was reported over roughly a year of treatment in defined populations of adults with obesity or overweight; the specific figures vary by drug, dose, and trial, so consult the current FDA label or the published trial for exact numbers. Those are study findings in defined trial populations, not a forecast of what any individual will experience. Your results, tolerability, and eligibility are between you and your clinician.

This is where the two platforms genuinely diverge, and it is the distinction most worth understanding before you choose.

Compounded GLP-1s are not FDA-approved. Compounded semaglutide and tirzepatide are prepared by compounding pharmacies rather than manufactured and approved as finished drugs by the FDA. Compounding is a long-standing, legal pharmacy practice, but compounded products do not carry FDA approval, are not reviewed by the FDA for safety and efficacy the way brand-name drugs are, and can vary between pharmacies. Both Henry Meds and Ivim Health offer compounded options, so this caveat applies to both — not as a knock on either, but as a fact every patient should weigh.

Brand-name drugs (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved. They are the products studied in the pivotal trials and carry full FDA labeling. They are also typically more expensive out of pocket and, at various points, have been subject to supply constraints.

Henry Meds is built primarily around compounded membership — it is the core of the offering. Ivim Health markets both compounded options and pathways toward brand-name medication, and emphasizes a more clinical wrapper around the prescription. If having a documented route to an FDA-approved branded GLP-1 matters to you, that tilts toward Ivim. If you are comfortable with a compounded product and want the lowest-friction, most predictable cash-pay experience, Henry's model is purpose-built for that.

We will not quote precise monthly figures we cannot stand behind, because pricing in this category moves frequently and varies by medication, dose, and plan. Here is the honest, structural picture.

Henry Meds markets a flat-rate, membership-style price for its compounded GLP-1 access — the appeal is predictability. You generally know your monthly number, it is cash-pay, and there is no insurance billing to chase. For a budget-focused patient who wants compounded medication and a stable line item, that transparency is the product.

Ivim Health prices as a program: the cost reflects not just medication but the clinical and coaching layer, and it varies depending on whether you are on a compounded or brand pathway. That can be better value if you actually use the coaching and clinical oversight, and a worse value if all you want is the cheapest possible compounded vial.

The right way to compare cost is total cost for the path you will actually take — medication plus membership plus any visit or lab fees — not the headline number. Confirm current pricing directly with each provider before enrolling; treat any figure you see, here or elsewhere, as subject to change.

This is the dimension where Ivim Health is designed to outperform. Ivim's pitch centers on a managed clinical experience — provider visits, lab review as part of the program, and a coaching component intended to support behavior change alongside the medication. For patients who do better with accountability and a human checking in, that structure has real value.

Henry Meds is intentionally lighter-touch. The model prioritizes a fast, low-friction path to medication with member support and messaging, rather than a heavy coaching apparatus. For a self-directed patient who wants the medication and not the hand-holding, that is a feature, not a gap.

Neither approach is inherently superior. The question is honest self-assessment: do you want a program that surrounds the prescription with coaching and labs (Ivim), or do you want efficient access and minimal overhead (Henry)?

Both platforms run their intake, messaging, and refills through a web portal experience rather than a heavy native-app workflow, and both aim to make reordering straightforward once you are an established patient. Ivim's portal carries more — visit scheduling and the coaching layer live there — while Henry's is built around the lean membership-and-refill loop.

On support, the trade-off mirrors the overall philosophy: Ivim's program structure means more touchpoints with clinical and coaching staff; Henry's leaner model means support is more transactional. We did not independently audit response times for either, so we are not going to claim one is categorically faster — that is exactly the kind of unverified specific we will not invent.

In the spirit of an honest review, here is the line between what is well-established and what we could not independently confirm.

What we are confident about: Both companies are telehealth platforms connecting patients to licensed clinicians; both require a consultation before any prescription; both offer compounded semaglutide and/or tirzepatide; compounded GLP-1s are not FDA-approved; brand-name GLP-1s are FDA-approved and studied in the pivotal trials; Henry Meds is structured around flat-rate compounded membership; Ivim Health emphasizes a more clinical, coaching-forward program with brand pathways.

What we could not independently verify and you should confirm at the source: exact current monthly prices and what each price includes; precise medication dosing tiers and how they affect cost; current shipping timelines; specific lab requirements; state-by-state provider availability; refund, pause, and cancellation terms; and exactly which brand-name products are available through Ivim at any given time. These details change, and they are the ones most likely to affect your real experience — get them in writing from the provider before you pay.

• You want the simplest, most predictable cash-pay compounded access: Henry Meds. The flat-rate membership and lean flow are built for exactly this.
• You want coaching, lab oversight, and a real clinical wrapper: Ivim Health. The program structure is the point.
• You want a credible route to brand-name (FDA-approved) GLP-1s: Ivim Health, which markets brand pathways alongside compounded.
• You are highly self-directed and cost-focused: Henry Meds. You will not pay for a coaching layer you would not use.
• You are new to GLP-1s and want more hand-holding: Ivim Health's coaching and clinical touchpoints suit first-timers who want support.

Whichever door you choose, the deciding step is the same: a consultation with a licensed provider who reviews your history and decides whether a GLP-1 is appropriate for you.

This article is educational and is not medical advice. It is intended for adults 18 and older. It does not diagnose, treat, cure, or prevent any condition, and nothing here is a promise of any result — individual outcomes, eligibility, and tolerability vary and are determined by you and a licensed clinician. A prescription for any GLP-1 medication requires a consultation with a licensed provider, who may decline to prescribe. Compounded medications are not FDA-approved and are regulated differently from brand-name drugs. Prices and program details are each provider's published figures and change frequently — verify current pricing and terms directly at the source before enrolling. GLP-1 Samples is an independent reviews site; it does not sell, ship, or prescribe medication, and placement is never for sale.